{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T08:57:42Z","timestamp":1785574662908,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00807-y","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T04:10:30Z","timestamp":1783311030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study"],"prefix":"10.1186","volume":"15","author":[{"given":"Sijian","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danian","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinquan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyang","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4015-3952","authenticated-orcid":false,"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"12","key":"807_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"8","key":"807_CR2","first-page":"617","volume":"42","author":"Leukemia","year":"2021","unstructured":"Leukemia, Lymphoma Group CSoHCMA. [Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021)]. Zhonghua Xue Ye Xue Za Zhi. 2021;42(8):617\u201323.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"3","key":"807_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000495206","volume":"141","author":"Z Li","year":"2019","unstructured":"Li Z, Liu Y, Wang Q, Chen L, Ma L, Hao S. Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of a Matched Identical Sibling: A Meta-Analysis. Acta Haematol. 2019;141(3):164\u201375.","journal-title":"Acta Haematol"},{"issue":"5","key":"807_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/ejh.12089","volume":"90","author":"BS Cho","year":"2013","unstructured":"Cho BS, Kim JH, Yoon JH, et al. Superior transplantation outcomes of 8\/8-matched unrelated donors as well as matched siblings to autologous transplantation for acute myeloid leukemia with intermediate cytogenetics in first remission. Eur J Haematol. 2013;90(5):365\u201374.","journal-title":"Eur J Haematol"},{"issue":"6","key":"807_CR5","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1158\/1078-0432.CCR-18-1637","volume":"25","author":"M Lv","year":"2019","unstructured":"Lv M, Wang Y, Chang YJ, et al. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. Clin Cancer Res. 2019;25(6):1737\u201348.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"807_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.bbmt.2017.12.796","volume":"24","author":"J Chen","year":"2018","unstructured":"Chen J, Yang L, Fan Y, et al. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission. Biol Blood Marrow Transpl. 2018;24(4):779\u201388.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"807_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/bmt.2016.233","volume":"52","author":"F Saraceni","year":"2017","unstructured":"Saraceni F, Bruno B, Lemoli RM, et al. Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission. Bone Marrow Transpl. 2017;52(1):163\u20136.","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"807_CR8","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/j.clml.2018.07.290","volume":"18","author":"W Limvorapitak","year":"2018","unstructured":"Limvorapitak W, Barnett MJ, Hogge DE, et al. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis. Clin Lymphoma Myeloma Leuk. 2018;18(11):e481\u201391.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"807_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamaoncol.2022.7605","volume":"9","author":"M Bornhauser","year":"2023","unstructured":"Bornhauser M, Schliemann C, Schetelig J, et al. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2023;9(4):519\u201326.","journal-title":"JAMA Oncol"},{"issue":"12","key":"807_CR10","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1182\/blood.V96.12.3948","volume":"96","author":"A Venditti","year":"2000","unstructured":"Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. 2000;96(12):3948\u201352.","journal-title":"Blood"},{"issue":"15","key":"807_CR11","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","volume":"36","author":"SD Freeman","year":"2018","unstructured":"Freeman SD, Hills RK, Virgo P, et al. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. J Clin Oncol. 2018;36(15):1486\u201397.","journal-title":"J Clin Oncol"},{"issue":"26","key":"807_CR12","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753\u201367.","journal-title":"Blood"},{"issue":"12","key":"807_CR13","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1182\/blood.2018886960","volume":"134","author":"A Venditti","year":"2019","unstructured":"Venditti A, Piciocchi A, Candoni A, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019;134(12):935\u201345.","journal-title":"Blood"},{"issue":"10","key":"807_CR14","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.3324\/haematol.2022.282639","volume":"108","author":"JM Tettero","year":"2023","unstructured":"Tettero JM, Ngai LL, Bachas C, et al. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. Haematologica. 2023;108(10):2794\u20138.","journal-title":"Haematologica"},{"issue":"12","key":"807_CR15","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/ajh.24904","volume":"92","author":"NC Gorin","year":"2017","unstructured":"Gorin NC, Labopin M, Pabst T, et al. Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission. Am J Hematol. 2017;92(12):1318\u201323.","journal-title":"Am J Hematol"},{"issue":"3","key":"807_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2991\/chi.k.210703.002","volume":"3","author":"NC Gorin","year":"2021","unstructured":"Gorin NC. History and Development of Autologous Stem Cell Transplantation for Acute Myeloid Leukemia. Clin Hematol Int. 2021;3(3):83\u201395.","journal-title":"Clin Hematol Int"},{"issue":"12","key":"807_CR17","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s41409-023-02070-9","volume":"58","author":"J Chen","year":"2023","unstructured":"Chen J, Labopin M, Pabst T, et al. Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT. Bone Marrow Transpl. 2023;58(12):1322\u201330.","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"807_CR18","doi-asserted-by":"publisher","first-page":"e2115991","DOI":"10.1001\/jamanetworkopen.2021.15991","volume":"4","author":"S Yu","year":"2021","unstructured":"Yu S, Fan Z, Ma L, et al. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes. JAMA Netw Open. 2021;4(7):e2115991.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"807_CR19","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201\u201312.","journal-title":"Lancet Oncol"},{"issue":"4","key":"807_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"5","key":"807_CR21","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/s41375-019-0686-3","volume":"34","author":"S Yu","year":"2020","unstructured":"Yu S, Huang F, Wang Y, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2020;34(5):1433\u201343.","journal-title":"Leukemia"},{"issue":"3","key":"807_CR22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ajh.26800","volume":"98","author":"H Liu","year":"2023","unstructured":"Liu H, Huang F, Zhang Y, et al. Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial. Am J Hematol. 2023;98(3):408\u201312.","journal-title":"Am J Hematol"},{"issue":"3","key":"807_CR23","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/S2352-3026(24)00372-7","volume":"12","author":"S Yu","year":"2025","unstructured":"Yu S, Huang F, Xu N, et al. Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2025;12(3):e190\u2013200.","journal-title":"Lancet Haematol"},{"issue":"27","key":"807_CR24","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391\u2013400.","journal-title":"Stat Med"},{"issue":"1","key":"807_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-016-0314-x","volume":"9","author":"F Saraceni","year":"2016","unstructured":"Saraceni F, Labopin M, Gorin NC, et al. Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. J Hematol Oncol. 2016;9(1):79.","journal-title":"J Hematol Oncol"},{"issue":"22","key":"807_CR26","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349\u201361.","journal-title":"JAMA"},{"key":"807_CR27","doi-asserted-by":"crossref","unstructured":"Bornhauser M, Schliemann C, Schetelig J et al. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2023.","DOI":"10.1001\/jamaoncol.2022.7605"},{"issue":"6","key":"807_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/MOH.0000000000000543","volume":"26","author":"O Fasan","year":"2019","unstructured":"Fasan O. Using minimal (measurable) residual disease assessments to guide decision-making for timing of allogeneic transplantation in acute myeloid leukemia. Curr Opin Hematol. 2019;26(6):413\u201320.","journal-title":"Curr Opin Hematol"},{"issue":"20","key":"807_CR29","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","volume":"121","author":"HH Zhu","year":"2013","unstructured":"Zhu HH, Zhang XH, Qin YZ, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121(20):4056\u201362.","journal-title":"Blood"},{"issue":"13","key":"807_CR30","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2009-12-258178","volume":"116","author":"F Buccisano","year":"2010","unstructured":"Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood. 2010;116(13):2295\u2013303.","journal-title":"Blood"},{"issue":"4","key":"807_CR31","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1182\/bloodadvances.2020003855","volume":"5","author":"B Lowenberg","year":"2021","unstructured":"Lowenberg B, Pabst T, Maertens J, et al. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv. 2021;5(4):1110\u201321.","journal-title":"Blood Adv"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00807-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00807-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00807-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T08:07:10Z","timestamp":1785571630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00807-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00807-y","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants signed written informed-consent forms. The study protocol was approved by the institutional review boards at each participating center. All procedures were in accordance with the ethical standards of the Ethics Committees and with the Helsinki Declaration before the initiation of the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"67"}}